Einstein Mount Sinai Diabetes Research Center

在过去的十年里，一系列引人注目的技术进步重新配置了 生物医学研究使用“免疫技术”，广泛收集有关的方法， 免疫系统研究中分析模式的量化、关联和可视化。尽管 然而，学术研究人员对这些技术的实施， 重大障碍，主要是需要随时获得适当的技术基础设施， 与测定性能相关的相当大的成本。为了应对这些挑战，新的免疫... 技术核心（ITC）被认为是一个教育、协调和服务的核心，将提供一个 这将是机构间合作的典范，并将是定向征聘和扩大 我们的糖尿病免疫学研究基地具体而言，国际贸易中心将把活动重点放在不同的技术上， 在与多个爱因斯坦-西奈山糖尿病研究中心的讨论中优先考虑的平台 （ES-DRC）研究人员，根据我们研究基地不断变化的研究需求。访问各自的 服务分布在爱因斯坦和西奈山; ITC将利用组合技术 基础设施，实现以下目标： 1.提高人们对Einstein和Mount提供的最先进技术基础设施的认识 Sinai（细胞、成像和免疫调节平台）;提供有关 各自技术的潜力和局限性;协助研究者进行实验规划， 关于预期财务投资的设计和考虑;并促进与 管理人员、应用科学家和数据分析专家与每个技术平台合作。 2.提供所需的支持服务，以有效和高效地实施量身定制的实验 协议.因此，ITC将侧重于特定试剂的选择、检测和验证; 调整和优化;以及与已建立的测定工作流程集成。 3.为便利使用选定的技术平台并提供实际支持：a） 细胞质量细胞计数法/飞行时间细胞计数法（CyTOF）; B）多重成像 免疫组织化学和全载玻片成像以及生物光子体内成像;以及c） 免疫调节-在Einstein开发的用于抗原特异性T细胞调节的synTac技术。 总的来说，国贸中心的服务和专门知识将通过以下方式支持和推动经济和社会事务部刚果民主共和国调查员的工作： 促进将尖端、复杂和成本高昂的技术整合到 他们的研究计划。被认为是研究胰岛生物学和 1型和2型糖尿病和肥胖的免疫学方面，ITC将支持现有的 ES-DRC的努力，并作为招聘新的调查人员在这些领域的工具。

Over the past decade, a succession of remarkable technological advances has reconfigured the landscape of biomedical research using “immuno-technologies”, the broad collection of methodologies pertaining to the quantification, correlation and visualization of analytical modalities in the study of the immune system. Despite their extraordinary promise, however, implementation of these technologies by academic researchers includes significant obstacles, chiefly the need for ready access to appropriate technological infrastructure and the considerable cost associated with assay performance. To address these challenges, the new Immuno- Technology Core (ITC) has been conceived as an education, coordination and service core that will provide a paradigm for inter-institutional cooperation and will be the focus of directed recruitment and expansion of our diabetes immunology research base. Specifically, the ITC will focus its activities on distinct technology platforms that have been prioritized in discussion with multiple Einstein-Mount Sinai Diabetes Research Center (ES-DRC) investigators, based on the evolving research needs of our research base. Access to respective services is distributed across both Einstein and Mount Sinai; the ITC will harness the combined technology infrastructure for the following objectives: 1. To raise awareness about select state-of-the-art technology infrastructure available at Einstein and Mount Sinai (cellular, imaging, and immunomodulation platforms); to provide consultation and advice about the potential and limitations of respective technologies; to assist investigators with experimental planning, design and considerations about expected financial investments; and to facilitate interactions with managers, application scientists and data analysis specialists working with each technology platform. 2. To provide support services required for the effective and efficient implementation of tailored experimental protocols. Accordingly, the ITC will focus on specific reagent selection, testing and validation; protocol adjustment and optimization; and integration with established assay workflows. 3. To facilitate access and provide practical support for the usage of selected technology platforms: a) cellular – mass cytometry / Cytometry by Time-of-Flight (CyTOF); b) imaging – multiplexed immunohistochemistry and whole-slide imaging as well as biophotonic in vivo imaging; and c) immunomodulation – synTac technology developed at Einstein for antigen-specific T cell modulation. Collectively, ITC services and expertise will support and advance the work of ES-DRC investigators by catalyzing the integration of cutting-edge, complex and otherwise often cost-prohibitive technologies into their research programs. Conceived as a novel and unique resource for the study of both islet biology and the immunological aspects of type 1 and type 2 diabetes and obesity, the ITC will both support existing ES-DRC efforts and serve as a recruiting tool for new investigators in these areas.